Imbruvica continues to impress as Phase 3 study stopped early


Pharmacyclics (PCYC) stops RESONATE (that's Phase 3 ibrutinib versus ofatumumab in relapsed or refractory CLL or SLL) early on the IDMC's recommendation, as Imbruvica hits its primary and key secondary endpoints.

Imbruvica shows statistically significant PFS and OS superiority.

Safety profile is "acceptable and consistent with prior clinical experience."

FDA and EMA have been notified (EMA by Janssen, JNJ). (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs